Psoriasis Stratification to Optimise Relevant Therapy (PSORT) is a stratified medicine consortium formed by world leading dermatologists, industry partners including pharmaceutical companies and psoriasis patients. Psoriasis is a chronic skin condition which affects more than 1.8 million people in the UK and can have a major impact of quality of life. The overall research strategy is to identify stratifiers of response to biologic therapies for patients with psoriasis.
Link to publication: Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study Journal of Investigative Dermatology. Volume 139, Issue 1, January 2019, Pages 115-123.